OBJECTIVES: The goal of this study was to evaluate the safety and efficacy of nicardipine in reversing no-reflow during percutaneous coronary intervention (PCI). BACKGROUND: No-reflow is a common complication of PCI in patients with acute coronary syndromes or venous bypass graft disease. Although nicardipine has an attractive pharmacological profile and has been used clinically to treat no-reflow, there is a paucity of published data regarding its effectiveness in this setting. METHODS: We conducted a retrospective analysis of 72 consecutive patients who received intracoronary nicardipine to reverse no-reflow during coronary intervention. Qualitative TIMI flow grade and quantitative TIMI frame count methods were used to assess the efficacy of nicardipine. RESULTS: A mean of 460 +/- 360 mcg of intracoronary nicardipine was used. No-reflow was successfully reversed with complete restoration of TIMI 3 flow in 71 of 72 patients (98.6%). TIMI flow grade improved from 1.65 +/- 0.53 prior to nicardipine to 2.97 +/- 0.24 after treatment (P < 0.001). TIMI frame count decreased from 57 +/- 40 at the time of no-reflow to 15 +/- 12 after nicardipine administration (P < 0.001). Nicardipine therapy was well tolerated without adverse hemodynamic or chronotropic effects. CONCLUSIONS: In this largest series to date, intracoronary nicardipine was demonstrated to be a safe and highly effective pharmacological agent to reverse no-reflow during PCI. (c) 2006 Wiley-Liss, Inc.
OBJECTIVES: The goal of this study was to evaluate the safety and efficacy of nicardipine in reversing no-reflow during percutaneous coronary intervention (PCI). BACKGROUND: No-reflow is a common complication of PCI in patients with acute coronary syndromes or venous bypass graft disease. Although nicardipine has an attractive pharmacological profile and has been used clinically to treat no-reflow, there is a paucity of published data regarding its effectiveness in this setting. METHODS: We conducted a retrospective analysis of 72 consecutive patients who received intracoronary nicardipine to reverse no-reflow during coronary intervention. Qualitative TIMI flow grade and quantitative TIMI frame count methods were used to assess the efficacy of nicardipine. RESULTS: A mean of 460 +/- 360 mcg of intracoronary nicardipine was used. No-reflow was successfully reversed with complete restoration of TIMI 3 flow in 71 of 72 patients (98.6%). TIMI flow grade improved from 1.65 +/- 0.53 prior to nicardipine to 2.97 +/- 0.24 after treatment (P < 0.001). TIMI frame count decreased from 57 +/- 40 at the time of no-reflow to 15 +/- 12 after nicardipine administration (P < 0.001). Nicardipine therapy was well tolerated without adverse hemodynamic or chronotropic effects. CONCLUSIONS: In this largest series to date, intracoronary nicardipine was demonstrated to be a safe and highly effective pharmacological agent to reverse no-reflow during PCI. (c) 2006 Wiley-Liss, Inc.
Authors: Vijayalakshmi Kunadian; Cafer Zorkun; Scott P Williams; Leah H Biller; Alexandra M Palmer; Katherine J Ogando; Michelle E Lew; Navin Nethala; William J Gibson; Susan J Marble; Jacqueline L Buros; C Michael Gibson Journal: J Thromb Thrombolysis Date: 2008-09-26 Impact factor: 2.300
Authors: Vijayalakshmi Kunadian; Caitlin Harrigan; Cafer Zorkun; Alexandra M Palmer; Katherine J Ogando; Leah H Biller; Erin E Lord; Scott P Williams; Michelle E Lew; Lauren N Ciaglo; Jacqueline L Buros; Susan J Marble; William J Gibson; C Michael Gibson Journal: J Thromb Thrombolysis Date: 2008-04-20 Impact factor: 2.300
Authors: Frans J Beerkens; Bimmer E Claessen; Marielle Mahan; Mario F L Gaudino; Derrick Y Tam; José P S Henriques; Roxana Mehran; George D Dangas Journal: Nat Rev Cardiol Date: 2021-10-05 Impact factor: 32.419